Smart Eye today announced 35 new design wins worth SEK700m - a combined order of five different OEMs...
Q2 details Sales SEK 730m (-1% vs ABG 740m, 0% vs cons 730m), adj.
Redeye expects Catella's Q2, due 21 August, to show a 19% y/y revenue decline with 11% EBIT margin (...
Redeye adds to its recent research notes about Sivers' intention to merge with US-listed SPAC byNord...
Net sales and EBITA were close to our expectations, excluding several one-off items in Q2.
Investors House reported Q2 2024 revenue of EUR 3.1m, 18% above our estimate, while net operating in...
Redeye comments on Embracer’s Q1-results where topline was slightly lower than expected while adjust...
Calliditas delivers a positive surprise in total sales, including royalty contributions from Asia, U...
Investors House reported Q2 revenues of EUR 3.1m, 18% above our EUR 2.
Redeye comments on Sozap’s Q2 results, which came in somewhat higher than expected on sales while EB...
Redeye comments on Verve Group’s preliminary Q2 2024 numbers, which came in stronger than expected, ...
Redeye leaves a comment following today’s encouraging news that Klaria has received market authoriza...
Aspo’s Q2 results were mostly as expected as ESL’s profitability topped estimates while Telko fell s...
Verve’s AI-driven, privacy-first advertising solutions are gaining good traction and market share is...
Redeye provides updated estimates and valuation following Physitrack’s Q2 report.
Redeye views the Q2 report as further confirmation of a successful strategy to already arrive at bei...
Q2e: US operations stable, Germany still struggling We expect Ferronordic to report Q2 net sales of ...
Redeye provides an update on Scandinavian ChemoTech following the Q2 2024 report.
Redeye retains its positive view of Fortnox despite Eklund stepping down as CEO.
Redeye saw a report where sales exceeded our expectations.
